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Value of the Data {#sec0001a}
=================

•The data provided are of value as there is currently only limited published data examining interference indices in body fluids submitted for clinical chemistry analyses.•Other researchers or personnel in clinical laboratories might find these data useful as a reference for comparison.•Our data set would serve as a starting point for researchers interested in future investigations examining the effects of hemolysis, icterus, and lipemia on body fluids analyzed by clinical chemistry assays marketed by vendors.•The data are of value as previous studies have not examined a wide range of clinical chemistry assays with respect to body fluid analysis and interference indices.•The data provide information for 2752 unique body fluid specimens and 25,507 serum/plasma specimens.

1. Data {#sec0001}
=======

We analyzed interference indices in body fluid and serum/plasma samples submitted for analysis at an academic medical center central clinical laboratory [@bib0001]. There is limited published data on interference indices in non-blood body fluids, and manufacturers of laboratory assays rarely provide data on the performance characteristics of body fluids for clinical chemistry assays [@bib0002], [@bib0003], [@bib0004], [@bib0005]. All data include patient age, legal gender in the electronic medical record, specific body fluid specimen, broader fluid category (abdominal fluid, cerebrospinal fluid, cyst contents, dialysate, drain fluids, gastric fluid, hepatic fluid, pancreatic fluid, pericardial fluid, pleural, respiratory secretions, stool, synovial fluid, urine, vaginal fluid, and wound exudate/fluid), quantitative hemolysis index, quantitative icteric index, quantitative lipemia index, clinical chemistry tests performed on the body fluid per clinician order and their quantitative analyte concentrations, and whether the interference indices exceed assay manufacturer thresholds in the assay package insert (which typically only reports interference limits for serum or plasma specimens). The raw data are included Supplementary file 1 (body fluids) and Supplementary file 2 (serum/plasma).•Supplementary file 1: Data for 2752 unique body fluid specimens divided into categories**.** Specific data fields include: location/unit at time of testing (emergency department, inpatient, or outpatient), age in years, legal gender, exact body fluid type, category of body fluid, hemolysis index, icteric index, lipemia index, and quantitative analyte concentrations for 12 different clinical chemistry assays (albumin, alkaline phosphatase, amylase, total bilirubin, blood urea nitrogen, total cholesterol, creatinine, glucose, lactate dehydrogenase, lipase, total protein, and triglyceride). The data include the quantitative analyte concentration for the clinical chemistry test (or "Unable to report" if no analyte concentration could be obtained) and whether the interference index exceeded the parameter for that analyte for serum/plasma as reported in the manufacturer package insert.•Supplementary file 2: Data for 25,507 unique serum/plasma specimens for 12 different clinical chemistry assays (albumin, alkaline phosphatase, amylase, total bilirubin, blood urea nitrogen, total cholesterol, creatinine, glucose, lactate dehydrogenase, lipase, total protein, and triglyceride). Specific data include hemolysis index, icteric index, lipemia index, and quantitative analyte concentrations for the different clinical chemistry assays. The data include the quantitative analyte concentration for the clinical chemistry test (or "Unable to report" if no analyte concentration could be obtained) and whether the interference index exceeded the parameter for that assay for serum/plasma as reported in the manufacturer package insert.

2. Experimental design, materials, and methods {#sec0002}
==============================================

All analyses were performed on Roche Diagnostics cobas 8000 analyzers (c502 and c702) as reported elsewhere [@bib0001],[@bib0006]. The raw data consist of hemolysis index, icteric index, and lipemia index along with the specific clinical chemistry tests performed. Reporting Workbench functionality within the electronic medical record (Epic, Epic Inc., Madison, WI, USA) and Healthcare Enterprise Decision Intelligence (HEDI; an institutional data warehouse), along with data from middleware software (Instrument Manager version 8.14, Data Innovations, Burlington, VT, USA) were used to retrieve the data [@bib0007],[@bib0008].
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